Years of translational research have paved the way to a therapeutic revolution of plaque psoriasis and more recently, atopic dermatitis. Severe trajectories are now commonly treated with biologics and small molecules rendering remarkable improvement for affected individuals in terms of quality of life. Rare and some common non-communicable inflammatory dermatoses (e.g. lichen planus, lichen sclerosus, cutaneous lupus erythematosus, neutrophilic dermatoses, granulomatous dermatoses) have fallen short and remain underserved until today with few or no licensed therapeutic options. However, the accessibility of cutaneous lesions enables researchers to apply sophisticated laboratory methods (e.g. single-cell sequencing, spatial omics) to decipher inflammatory pathways in lesional and non-lesional skin in respective patients, deepening our understanding of the underlying pathophysiology. Targeted interleukin- and tyrosine kinase inhibition as well as receptor blockade are transferred increasingly to clinical trials. The therapeutic landscape might change distincly in the near future.
The goal of this research topic is to compile articles dealing with underserved inflammatory dermatoses to showcase potential therapeutic advancements. The topic of interest spans from basic research and its clinical implications to challenges in daily practice and clinical trials (including inconsistency of endpoints and variables between patients of different sex and ethnic groups). This research topic also aims to be a forum to report early experiences with visionary treatments in the setting of the aforementioned diseases. Ultimately, we strive to collect cutting-edge articles that may serve as signpost for developments to expect in underserved inflammatory dermatoses in the upcoming decade.
• Lichenoid dermatoses (e.g. lichen planus and variants, lichen sclerosus)
• Cutaneous lupus erythematosus
• Cutaneous connective tissue disease (e.g. dermatomyositis, MCTD, systemic and localized scleroderma)
• Neutrophilic dermatoses (e.g. Sweet’s syndrome, pyoderma gangraenosum, Behcet syndrome)
• Granulomatous dermatoses (e.g. sarcoidosis, granuloma annulare, necrobiosis lipodica)
• Types of articles suitable: Original research, systematic reviews, reviews, mini reviews, hypothesis and theory, perspective, case reports, brief research report, opinion
Keywords:
Lichen Planus, Lichen Planus Oral, Lichen planus follicularis, Lichen Sclerosus et Atrophicus, Vulvar Lichen Sclerosus, Lupus Erythematosus, Cutaneous, Connective Tissue Diseases, Sarcoidosis, Granuloma, Necrobiosis Lipoidica
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Years of translational research have paved the way to a therapeutic revolution of plaque psoriasis and more recently, atopic dermatitis. Severe trajectories are now commonly treated with biologics and small molecules rendering remarkable improvement for affected individuals in terms of quality of life. Rare and some common non-communicable inflammatory dermatoses (e.g. lichen planus, lichen sclerosus, cutaneous lupus erythematosus, neutrophilic dermatoses, granulomatous dermatoses) have fallen short and remain underserved until today with few or no licensed therapeutic options. However, the accessibility of cutaneous lesions enables researchers to apply sophisticated laboratory methods (e.g. single-cell sequencing, spatial omics) to decipher inflammatory pathways in lesional and non-lesional skin in respective patients, deepening our understanding of the underlying pathophysiology. Targeted interleukin- and tyrosine kinase inhibition as well as receptor blockade are transferred increasingly to clinical trials. The therapeutic landscape might change distincly in the near future.
The goal of this research topic is to compile articles dealing with underserved inflammatory dermatoses to showcase potential therapeutic advancements. The topic of interest spans from basic research and its clinical implications to challenges in daily practice and clinical trials (including inconsistency of endpoints and variables between patients of different sex and ethnic groups). This research topic also aims to be a forum to report early experiences with visionary treatments in the setting of the aforementioned diseases. Ultimately, we strive to collect cutting-edge articles that may serve as signpost for developments to expect in underserved inflammatory dermatoses in the upcoming decade.
• Lichenoid dermatoses (e.g. lichen planus and variants, lichen sclerosus)
• Cutaneous lupus erythematosus
• Cutaneous connective tissue disease (e.g. dermatomyositis, MCTD, systemic and localized scleroderma)
• Neutrophilic dermatoses (e.g. Sweet’s syndrome, pyoderma gangraenosum, Behcet syndrome)
• Granulomatous dermatoses (e.g. sarcoidosis, granuloma annulare, necrobiosis lipodica)
• Types of articles suitable: Original research, systematic reviews, reviews, mini reviews, hypothesis and theory, perspective, case reports, brief research report, opinion
Keywords:
Lichen Planus, Lichen Planus Oral, Lichen planus follicularis, Lichen Sclerosus et Atrophicus, Vulvar Lichen Sclerosus, Lupus Erythematosus, Cutaneous, Connective Tissue Diseases, Sarcoidosis, Granuloma, Necrobiosis Lipoidica
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.